Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRATIFY adalimumab-800CW near-infrared fluorescence imaging study
NL-OMON59542Phase 1Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of adalimumab in Crohn's disease, autoimmune colitis, rheumatoid arthritis (RA) and 1 more (4 cohorts), sponsored by University Medical Center Groningen. Started Aug 2024; status: recruiting.
02
Drugs
03
Conditions
Crohn's diseaseautoimmune colitisrheumatoid arthritis (RA)spondyloarthritis (SpA)
Beyond the preview
Go deeper on NL-OMON59542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59542.